

Haematologica
HAEMATOL/2017/184564
Version 3

Outcomes of patients with relapsed aggressive adult T-cell
leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and
allogeneic hematopoietic stem cell transplantation

Shigeo Fuji, Atae Utsunomiya, Yoshitaka Inoue, Takashi Miyagi,
Satsuki Owatari, Yasushi Sawayama, Yukiyoshi Moriuchi, Ilseung Choi,
Takeru Shindo, Shin-ichiro Yoshida, Satoshi Yamasaki, Takuhiro
Yamaguchi, and Takahiro Fukuda

Disclosures: S.F. received honoraria from Kyowa Hakko Kirin Co., Ltd.; T.Y. had ownership interests of Statcom Co., Ltd., received consulting fees from Ono Pharmaceutical Co., Ltd., honoraria from Taiho Pharmaceutical Co., Ltd., and research funding from Kyowa Hakko Kirin Co., Ltd.; and A.U. received honoraria from Japan Blood Products Organization, Roche Diagnostics, Daiichi Sankyo, Siemens, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Kyowa Hakko Kirin, Novartis Pharma, HUYA Bioscience International, Nippon Shinyaku, Chugai Pharma and Celgene, Immuno-Biological Laboratories, and Sumitomo Dainippon Pharma.

Contributions: S.F., T.Y., Y.I., and T.F. participated in research design, data analysis, and manuscript writing. A.U., T.M., S.O., Y.S., Y.M., I.C., T.S., S.Y., and S.Y. gathered the data. All authors approved the submission of this manuscript.